Our findings suggest that FGF21D2D3 is a more potent and effective protein than FGF21WT for treating DCM through improving dyslipidemia and directly inhibiting oxidative stress via FGFR1–AMPK activation in T2D. This evidence concerns the gene FGFR1 and type 2 diabetes mellitus.